Program Book

Recommendations

Info

homogeneous and gives the whole dose to the bulbar and tarsal conjunctiva. Results. We report results from 24 HIV negative patients who received proton radiotherapy in Nice between 2001 and 2010. Mean follow up is 40 months. None of the patients died for metastases. Tumor control was achieved for 19 patients (79%). 5 recurrent tumors were observed 2 – 8 years after the irradiation. None of them occurred inside the irradiated volume. In one case, a second proton irradiation could control the disease. Exenteration was performed in the other cases. Conclusion. Proton irradiation offers the possibility to successfully treat SCC of the conjunctiva with acceptable side effects and can be considered as an alternative to traditional treatments. Financial disclosure: None 1505 EC10 PROSPECTIVE STUDY OF SENTINEL LYMPH NODE BI- OPSY FOR CONJUNCTIVAL MALIGNANT MELANOMA Victoria M.L. Cohen, Maria Tsimpida, Norbert Avril, John L. Hungerford, Grahem Moir (victoria.lendrum@gmail.com) Ocular Oncology Service. St Bartholomew’s and Moorfields eye Hospital, London UK Department of Nuclear Medicine, St Bartholomew’s Hospital, London UK Department of Plastic Surgery, St Bartholomew’s Hospital London UK Purpose. To report our experience with sentinel lymph node biopsy for staging patients with conjunctival malignant melanoma. Methods. All patients with conjunctival malignant melanoma who had sentinel lymph node biopsy at St. Bartholomew’s Hospital from May 2008 to May 2011 were included in this study. The main outcome measures were the incidence of sentinel lymph node positivity, the procedure-related complications and the metastasis free survival rate. Results. In 3 years, 23 patients met the selection criteria for sentinel lymph node biopsy. 4 patients declined and 19 patients were consented for the procedure. Technetium-99m failed to identify the lymph nodes in 4 of the 19 patients (21%). Of the remaining 15 patients, 2 were found to have subclinical micrometastasis in regional lymph nodes. No false-negative events were observed. Complications of the procedure included transient blue staining of the epibulbar surface in 3 patients and transient facial nerve palsy in 1 patient. Conclusions. Sentinel lymph node biopsy is a safe procedure with minimal complications. It should be considered for the staging of conjunctival melanoma, especially non-limbal melanoma or conjunctival melanoma more than 2mm thick. Financial disclosure. None 2202 EC11 EXENTERATION FOR CONJUNCTIVAL MELANOMA IN LIVERPOOL: 1993-2010 Nihal Kenawy, Sarah E. Coupland, Bertil E. Damato (nkenawy@liverpool.ac.uk) Liverpool Ocular Oncology Centre, Royal Liverpool University Hospital, Prescot Street, Liverpool, UK Purpose. To report the incidence and causes of exenteration in patients with conjunctival melanoma treated at the Liverpool Ocular Oncology Centre (LOOC) between 1993 and 2010. Methods. Database review of all patients with conjunctival melanocytic disease treated in LOOC between 1993 and 2010. Patients treated with exenteration were identified and the case notes were reviewed to EYELID, CONJUNTIVA & ORBIT Abstracts 70 identify the reasons for exenteration. Results. We treated 99 patients (52 females, 47 males; median age 62 years, range 24-95) for conjunctival melanoma between 1993 and 2010. Four patients required exenteration. Two were males and two females. At initial presentation, three patients had biopsy-proven invasive melanoma and one patient had melanoma in situ (C-MIN score 9). One patient had primary exenteration because of advanced disease at presentation and three had secondary exenteration because of uncontrollable disease and/or pain. One of the three patients commenced treatment in 1995 prior to our updated policy of brachytherapy for invasive melanoma and the condition was uncontrolled with multiple sessions of topical mitomycin C and cryotherapy. The caruncle and lacrimal passages were involved in the two other patients with invasive melanoma, both of whom had undergone excision biopsy with inadequate clearance prior to referral to LOOC. Both patients had received adjunctive orbital radiotherapy but one developed distant metastasis. Conclusions. Exenteration for conjunctival melanoma is rare in patients undergoing primary treatment with adjunctive brachytherapy and topical chemotherapy. The main causes of exenteration were uncontrollable disease and pain. Financial disclosure. None 2311 EC12 TEENAGE ELEVATED CONJUNCTIVAL LESIONS IN THE PLICAL AREA – LYMPHOMA OR REACTIVE LYMPHOID HYPERPLASIA? Shahar Frenkel, MD, PhD, Jacob Pe’er, MD(shahar.frenkel@gmail.com) Specialized Ocular Oncology Service, Department of Ophthalmology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel Purpose. Ocular adnexal lymphoma (OAL) comprises 2.5% of extranodal non-Hodgkin lymphomas, and is most commonly a marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT). The mean age at diagnosis is 63, with only 1.4% of cases younger than 21 years of age. We describe a series of cases with a similar clinical presentation but with a different final diagnosis in teenage patients. Methods. Retrospective chart review of patients with a clinical presentation of indicative of teenage OAL, presenting to our clinic in the past 5 years. Results. Five teenagers aged 14-17, all male, presented with bilateral large elevated pink conjunctival masses immediately adjacent to or even connected to the plica. None of them complained of allergic symptoms on presentation, but 3 (cases 3-5) confirmed symptoms on questioning. Cases 1-3 did not respond to anti-allergic medications and underwent excisional biopsies that revealed MALT lymphoma in cases 1 and 2, and reactive lymphoid hyperplasia in case 3. Cases 4 and 5 were treated with anti-allergic medication with resolution of the findings, and were clinically diagnoses as reactive lymphoid hyperplasia. Conclusions. OAL is rare in the pediatric group, but reactive lymphoid hyperplasia can present in teenage (male) patients with large plical masses that can resemble OAL. Financial disclosure. None 1933 OT1 CLINICAL SURVEY OF 3680 SOLID AND CYSTIC TU- MORS OF THE IRIS Carlos Bianciotto, Carol L Shields, Swarupa Kancherla, Mayerling Suriano, Margaret V. Shields, Priya Sharma, Jinali Patel, Jerry A. Shields
(cargusale@yahoo.com) Oncology Service, Wills Eye Institute, Philadelphia Purpose. To report the spectrum of iris lesions from a single ocular oncology center Methods. Retrospective review of medical records Results. Of 3451 patients, the mean age at presentation was 48 years (median 50 years, range 2 week to 95 years). There were 1423 males (41%) and 2028 females (59%). Of 3680 lesions, 2907 (79%) were benign and 773 (21%) were malignant, while 768 were cystic (21%) and 2912 (79%) solid. Specific diagnoses included nevus (41%), iris pigment epithelium (IPE) cyst (18%), melanoma (18%), freckle (3%), Lisch nodules (2%), melanocytoma (2%), melanocytosis (2%), and other (15%). Lesions were located in the iris stroma (80%) and IPE (20%). Most common diagnostic categories within solid lesions were melanocytic (68%), non-melanocytic (11%), vascular (2%), metastasis (2%) and pseudotumors (5%). Conclusions. Of 3680 iris lesions, 79% were benign; and the most common diagnosis included nevus (41%), IPE cyst (18%), melanoma (18%), and freckle (3%). Financial disclosure. None 111 OT2 CLINICAL AND OCT FINDINGS ON SYMPTOMATIC MACULAR NAEVI TREATED WITH INTRAVITREAL ANTI-VEGF Sonia A. Callejo, Mikael Sebag, Marc Blouin, Christine Corriveau (guilleyso@hotmail.com) Centre Hospitalier de l’Universite de Montreal CHUM Canada Purpose. To report the clinical and OCT findings of patients with symptomatic macular naevi treated with intraocular anti-VEGF. Methods. Retrospective small case series of 8 patients diagnosed with macular choroidal naevus with impared visual acuity treated with intravitreal anti-VEGF. Clinical information, serial color fundus photography, FA, OCT findings and ultrasonographic tumor measurements were reviewed and compared before and after anti-VEGF treatment. Results. 8 patients: 4 males and 4 females. Mean age at presentation: 63 years (range 49 to 54). Mean follow up: 3 ½ years (range 7 months-9 1/2 years). Mean number of anti-VEGF injections: 7.5 (range: 1 to 17). The largest naevus basal diameter was 7.3mm and the median thickness was 2.1mm. No ultrasonographic evidence of tumor enlargement or transformation into melanoma was documented following treatments. Large fluctuations in VA were recorded prior to anti-VEGF injections. Reduction in the degree of fluctuation was noticed during anti-VEGF treatments. Anti-VEGF treatment was associated with resolution or decreased of exudative retinal detachment, retinal thickness, cystic retinal changes (4 cases), subretinal fluid (6 cases), pigmented epithelium detachment (PED) (3 cases) and subretinal/intraretinal blood associated (1 case) or not (2 cases) to the presence of a choroidal endovascular membrane. Conclusions. Although a larger study is needed, the use of intraocular anti-VEGF treatment of symptomatic macular naevi is promising based on the improvement of clinical and OCT parameters as well as the stability of tumor measurements. Financial disclosure. None EYELID, CONJUNTIVA & ORBIT Abstracts 71 1340 OT3 RISK FACTORS FOR GROWTH OF POSTERIOR UVEAL MELANOCYTIC LESIONS WITH THICKNESS GREATER THAN 2 MM IN 161 CONSECUTIVE PATIENTS Patrick De Potter, Audrey Noel, Jacques Jamart (patrick.depotter@uclouvain.be) Ocular Oncology Unit, Centre du Cancer, Cliniques Universitaires St Luc, Brussels, Belgium. Centre de Biostatistique et de Documentation médicale, Cliniques Universitaires de Mont-Godinne, Yvoir, Belgium Purpose. To better define the clinical and ultrasonographic risk factors predictive of growth of small melanocytic posterior uveal tumors presenting with a thickness of 2 mm or more as the only clinical suspicious factor predictive of tumor growth at first visit. Methods. Non comparative observational cases series including 161 patients with suspicious choroidal or cilio-choroidal tumors measuring 2 mm or more in thickness and no other clinical factors predicting of growth such as orange pigment, subretinal fluid, tumor margin touching disc, or tumor-related visual symptoms at initial visit. Those 161 patients were followed since October 1997 to document growth prior to treatment. Kaplan-Meier analysis was used to assess time to tumor growth and Cox proportional hazards regressions evaluated factors predictive of tumor growth Results. The mean age at diagnosis was 65 years old. The mean largest tumor diameter was 9 mm (range, 3 to 16 mm) and tumor thickness 2,6 mm (range, 2 to 5,6 mm). The mean distance to the disc was 5,7 mm (range, 0,5 to 15 mm) and to the fovea 5,2 mm (range, 0 to 16 mm). Of the 161 small melanocytic lesions, 31 (19%) demonstrated growth after a mean follow-up of 32 months (range, 6 to 116 months). One patient (0.6%) developed systemic metastasis. The factors predictive of growth included greater tumor diameter, greater tumor thickness, lack of drusen, and acoustic hollowness. The global cumulative risks for tumor growth were 4% at one year, 17% at 3 years, 22% at 5 years, and 27% at 10 years. Conclusions. Among posterior uveal melanocytic lesions with tumor thickness greater than 2.0 mm as the only clinical factor predictive of growth at initial visit, those with greater diameter, greater thickness, acoustic hollowness and lack of overlying drusen carried a significant risk for growth and should be monitored with regular surveillance. Financial disclosure. None 6 OT4 THE EXPANDING SPECTRUM OF RETINAL VASOPRO- LIFERATIVE TUMOURS Jerry A. Shields MD, David Reichstein MD, Arman Mashayekhi MD, Carol L. Shields MD (jerryshields@comcast.net) Wills Eye Institute Purpose. Retinal vasoproliferative tumor (RVPT) was originally described as an idiopathic fundus lesion with distinct clinical features. Subsequently, it found to be associated with a variety of ocular and systemic conditions and was subdivided into primary and secondary types. Methods. Review of lesions coded as retinal RVPT on the Oncology Service of Wills Eye Institute and literature search for causes of secondary retinal RVPTs Results. The secondary form of RVPT has now been associated with a
Page 1 and 2:
XV th NH City Hotel and Tower Boliv
Page 3 and 4:
List of Congress Meetings of the In
Page 5:
Table of Contents Welcome address K
Page 8 and 9:
Keynote Lectures Lymphoma of the oc
Page 10 and 11:
The venue for the Biannual Meeting
Page 12 and 13:
Buenos Aires Downtown MAP 12 Venue
Page 15 and 16:
MORNING 8.30-10.10 Papers (Moderato
Page 17 and 18:
50 RES 26 USING THE GLYCOLYTIC INHI
Page 19 and 20: 2226 RES 4 NOTCH SIGNALING PROMOTES
Page 21 and 22: a reduction in the number of living
Page 23 and 24: array further detected copy number
Page 25 and 26: 615 RES 21 TRB2 AND SKP2 IN THE RET
Page 27: following treatment with 2-fluorode
Page 30 and 31: 1909 Rb14 RESULTS OF PATIENTS WITH
Page 32 and 33: Posters Retinoblastoma 2006 RBp100
Page 34 and 35: 120 RBp135 MANAGEMENT OF AN ECTOPIC
Page 36 and 37: After treatment, 10 patients lived
Page 38 and 39: Methods. Six cycles of carboplatin
Page 40 and 41: 1940 RB15 PROTON THERAPY FOR RECURR
Page 42 and 43: 4. Fluoroscopy for cannula placemen
Page 44 and 45: Methods. A retrospective chart revi
Page 46 and 47: Ruth A. Kleinerman1, Chu-ling Yu1,
Page 48 and 49: 2006 RBp100 RETINOBLASTOMA ASSESSME
Page 50 and 51: months. Mean delay between beginnin
Page 52 and 53: not associated with severity of RB.
Page 54 and 55: Conclusions. During a ten-year peri
Page 56 and 57: 30 RBp127 TREATMENT MODULATION IN R
Page 58 and 59: (follow-up 5 years). Two years afte
Page 61 and 62: 8.30-9.00 Poster presentations ECOp
Page 63 and 64: Uvea (Moderators: B. Damato, M. Sag
Page 65 and 66: Morning 8.30-9.00 Poster presentati
Page 67 and 68: 1621 EC1 EVALUATION OF THE “HEDGE
Page 69: Purpose. Ocular surface squamous ne
Page 73 and 74: of the tissues most commonly affect
Page 75 and 76: 2128 RF1 RETINOBLASTOMA David H. Ab
Page 77 and 78: Ocular Oncology Service, St Barthol
Page 79 and 80: Arturo Irarrazaval, Pablo Cazon, Os
Page 81 and 82: A CASE OF TEARING AND SWELLING OF T
Page 83 and 84: 1849 ECp101 FIVE CASES OF CARCINOMA
Page 85 and 86: patients. The isolated involvement
Page 87 and 88: exudative fluid from the hemangioma
Page 89: maximum of 7 rituximab injections.
Page 92 and 93: 153 UM14 PHENO-GENOTYPIC IDENTIFICA
Page 94 and 95: 8.30-9.00 Poster presentations UMp1
Page 96 and 97: 2253 UM1 PRELIMINARY STUDY OF VASCU
Page 98 and 99: Purpose. To determine the presence
Page 100 and 101: gene expression profile of melanocy
Page 102 and 103: the rarity of UM, timely completion
Page 104 and 105: C. Metz, T. Gkika, W. Sauerwein, N.
Page 106 and 107: Patients in the triamcinolone group
Page 108 and 109: 1350 Ump101 INDUCED EXPRESSION OF P
Page 110 and 111: Purpose. To report the Results of R
Page 112 and 113: 1547 Ump113 LONG-TERM OBSERVATIONS
Page 114 and 115: 2038 Ump119 VALUE OF DOPPLER ANALYS
Page 116: Methods. A total of 4070 patients w
Page 119: First authors Naseripour, Masood No
show all

Program Book

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?